Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-101 + gemcitabine + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Scandion Oncology
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
SCO-101 + gemcitabine + nab-paclitaxel is an experimental combination therapy under clinical investigation for advanced or metastatic pancreatic ductal adenocarcinoma and other cancers. SCO-101 is an oral small molecule known to inhibit the drug efflux pump ABCG2 (BCRP), the serine/arginine protein kinase 1 (SRPK1), and the liver enzyme UGT1A1. By inhibiting these resistance mechanisms, SCO-101 is designed to sensitize cancer cells to chemotherapies by increasing intracellular drug concentrations and modulating cell survival pathways. Both gemcitabine and nab-paclitaxel are established cytotoxic chemotherapies for pancreatic cancer. Nab-paclitaxel is a nanoparticle albumin-bound form of paclitaxel, which, alongside gemcitabine, is standard of care for first- and second-line metastatic pancreatic cancer treatment. The combination aims to overcome pharmacological resistance mechanisms and improve antitumor efficacy. SCO-101 is in clinical development by Scandion Oncology and has been tested in phase Ib/II trials with gemcitabine and nab-paclitaxel in pancreatic cancer, showing manageable toxicity but no clear additional efficacy signal so far[5][1].
- Other names
- nab-paclitaxel
02
Targets
RNR (Ribonucleotide reductase)SRPK1 (Serine/arginine-rich protein-specific kinase 1)UGT1A1 (UDP-glucuronosyltransferase 1A1)ABCG2 (Breast cancer resistance protein)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SCO-101 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-101 + gemcitabine + nab-paclitaxel.